二陈三子汤加味治疗痰浊阻肺型慢性阻塞性肺疾病急性加重期的临床效果

Clinical Effect of Modified Erchen Sanzi Decoction on Acute Exacerbation of Chronic Obstructive Pulmonary Disease with Phlegm Turbidity Obstructing the Lung

目的:探讨二陈三子汤加味治疗痰浊阻肺型慢性阻塞性肺疾病急性加重期(AECOPD)的临床效果。方法:选择清流县总医院2018年12月-2020年12月收治的96例痰浊阻肺型AECOPD患者为研究对象,再以统计学软件SAS的随机数模块分成对照组(n=48)、观察组(n=48),前者常规西医治疗,后者在常规西医治疗的基础上以二陈三子汤加味治疗,两组均治疗2周。比较两组治疗效果、中医症候积分、肺功能指标、血气指标、不良反应发生率。结果:观察组治疗总有效率93.75%,高于对照组的75.00%,差异有统计学意义(χ^(2)=6.400,P<0.05)。治疗前两组咳嗽、喘息、咳痰、胸满中医症候积分对比,差异无统计学意义(P>0.05);治疗后观察组上述症状积分低于对照组(t=7.083、6.653、5.371、6.889,P<0.05)。治疗前两组第1秒用力呼气容积(FEV_(1)),一秒率(FEV_(1)%)对比差异无统计学意义(P>0.05);治疗后观察组FEV_(1)、FEV_(1)%高于对照组(t=2.545、4.047,P<0.05)。治疗前两组动脉血氧分压、动脉血二氧化碳分压对比差异无统计学意义(P>0.05);治疗后观察组动脉血氧分压高于对照组,动脉血二氧化碳分压低于对照组(t=3.893、3.378,P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:二陈三子汤加味在治疗痰浊肺阻型AECOPD中具有理想效果,可促进疾病症状的缓解,使患者肺功能、血气指标得到改善;并且二陈三子汤加味治疗的安全性高,不良反应风险低,具有推广价值。

Objective:To explore the clinical efficacy of modified Erchen Sanzi Decoction in the treatment in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with phlegm turbidity obstructing the lung.Method:A total of 96 patients with AECOPD with phlegm turbidity obstructing the lung treated in Qingliu County General Hospital from December 2018 to December 2020 were taken as the research objects,and then divided into control group (n=48) and observation group (n=48) with the random number module of statistical software SAS.The former was treated with conventional western medicine,the latter was treated with modified Erchen Sanzi Decoction on the basis of conventional western medicine,and the patients in the two groups were treated for 2 weeks.The treatment effect,the changes of TCM syndrome score,the changes of pulmonary function index,the changes of blood gas index and the incidence of adverse reactions were compared between the two groups.Result:The total effective rate in the observation group was 93.75%,which was higher than 75.00% in the control group,the difference was statistically significant (χ^(2)=6.400,P<0.05).There were no significant differences in TCM syndrome score of cough,wheezing,expectoration and chest fullness between the two groups before treatment (P>0.05).After treatment,the above scores in the observation group were lower than those in the control group (t=7.083,6.653,5.371,6.889,P<0.05).There were no significant differences in forced expiratory volume in one second (FEV_(1)) and forced expiratory volume in one second/forced vital capacity (FEV_(1)%) between the two groups before treatment (P>0.05).After treatment,FEV_(1)and FEV_(1)% in the observation group were higher than those in the control group (t=2.545,4.047,P<0.05).There were no significant differences in arterial oxygen partial pressure and arterial carbon dioxide partial pressure between the two groups before treatment (P>0.05).After treatment,the arterial oxygen partial pressure in the observation group was higher than that in the control group,and the arterial carbon dioxide partial pressure was lower than that in the control group (t=3.893,3.378,P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion:Modified Erchen Sanzi Decoction has ideal curative effect in the treatment of AECOPD with phlegm turbidity obstructing the lung,which can promote the remission of disease symptoms and improve patients’ lung function and blood gas indexes.Moreover,the modified Erchen Sanzi Decoction has high safety and low risk of adverse reactions,so it has popularization value.